Research Highlights

Please join us to congratulate Prof Eric Chan and his team on their latest publication in the Cancer Communications (JCR, IF 24.9) , titled “Evaluation of exposure-response-safety relationship of model-informed low-dose 500 mg abiraterone acetate in prostate cancer patients”. The online article can be accessed here: https://doi.org/10.1002/cac2.70035

The research found that 500 mg abiraterone acetate led to a PSA reduction in all patients after 12 weeks, with over 75% experiencing a drop of 50% or more. The lower dose treatment was generally safe and well tolerated. Importantly, advanced pharmacokinetic modelling showed that even at half the usual dose, over 80% of the drug’s target enzyme (CYP17A1) remained inhibited, indicating strong therapeutic activity. These findings build on prior research and support the feasibility of a scientifically guided, lower dose strategy.

Read more: Lower dose of abiraterone acetate as effective for prostate cancer treatment – NUS Faculty of Science